4.5 Review

COPD symptoms in the morning: impact, evaluation and management

Journal

RESPIRATORY RESEARCH
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1465-9921-14-112

Keywords

Morning symptoms; Onset of action; Once-daily; Long -acting muscarinic antagonists; Long-acting beta(2) agonists

Funding

  1. Aerocrine
  2. Almirall
  3. Altana Pharma-Nycomed
  4. AstraZeneca
  5. Boehringer Ingelheim
  6. Chiesi
  7. GlaxoSmithKline
  8. MEDA
  9. MSD-Chibret
  10. Mundipharma
  11. Novartis
  12. Pfizer
  13. Teva
  14. Bayer Schering
  15. Talecris-Grifols
  16. Takeda-Nycomed
  17. Merck, Sharp Dohme
  18. GSK

Ask authors/readers for more resources

Chronic obstructive pulmonary disease (COPD) symptoms in the morning, including dyspnea and sputum production, affect patients' quality of life and limit their ability to carry out even simple morning activities. It is now emerging that these symptoms are associated with increased risk of exacerbations and work absenteeism, suggesting that they have a more profound impact on patients than previously thought. The development of validated patient-reported outcome (PRO) questionnaires to capture patients' experience of COPD symptoms in the morning is, therefore, vital for establishing effective and comprehensive management strategies. Although it is well established that long-acting bronchodilators are effective in improving COPD symptoms, the limited available data on their impact on morning symptoms and activities have been obtained with non-validated PRO questionnaires. In this review, we discuss the impact of COPD symptoms in the morning and available tools used to evaluate them, and highlight specific gaps that need to be addressed to develop standardized instruments able to meet regulatory requirement. We also present available evidence on the effect of pharmacological therapies on morning symptoms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available